Focus: Septerna is a pre-clinical/early-stage biotech focused on GPCR drug discovery with programs in neurology. The company operates from South San Francisco with a lean, focused team.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Stable — net -2 jobs in 30d
2 added, 4 removed. Backfill posture.
Septerna is a high-risk, high-reward discovery-stage bet suitable for scientists and operators who thrive in lean environments and can tolerate 5+ years to clinical validation.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Septerna
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Septerna's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles